Samik Pharm.
Financials
Valuation Metrics
Samik Pharm.'s Market Cap is ₩468B. Ranked #1781 of 2,436 in KR market (top 73%), #1082 of 1,649 on KOSDAQ (top 66%), #194 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 83%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 46.81B KRW | KR#1,781/2,436 Sec#194/234 |
| Revenue | 60.02B KRW | KR#1,684/2,436 Sec#112/234 |
| Net Income | -754.9M KRW | KR—/2,436 Sec—/234 |
| Total Assets | 85.22B KRW | KR#1,863/2,436 Sec#153/234 |
| Net Assets | 68.98B KRW | KR#1,653/2,436 Sec#141/234 |
| Value | ||
| P/B | 0.68x | KR#1,120/2,436 Sec#60/234 |
| P/S | 0.78x | KR#1,224/2,436 Sec#65/234 |
| EV/EBITDA | 13.53x | KR#798/2,436 Sec#44/234 |
| FCF Yield | -2.88% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -1.09% | KR#1,569/2,436 Sec#109/234 |
| ROA | -0.89% | KR#1,587/2,436 Sec#110/234 |
| Op. Margin | 5.45% | KR#866/2,436 Sec#69/234 |
| Financial Health | ||
| Debt Ratio | 123.54% | KR#737/2,436 Sec#89/234 |
| Total Debt | 2.68B KRW | KR#1,872/2,436 Sec#181/234 |
| FCF | -1.35B KRW | KR#1,299/2,436 Sec#99/234 |
| Cash | 5.22B KRW | KR#1,971/2,436 Sec#177/234 |
| Current Ratio | 4.85x | KR#306/2,436 Sec#58/234 |
| Net Debt/EBITDA | -0.77x | KR#516/2,436 Sec#30/234 |
| Dividend | ||
| Div. Yield | 0.90% | KR#1,171/2,436 Sec#72/234 |
| Performance | ||
| 1M Return | -11.76% | KR#1,860/2,436 Sec#188/234 |
| From 52W High | -81.44% | KR#2,369/2,436 Sec#227/234 |
| 1Y MDD | -81.92% | KR#2,328/2,436 Sec#221/234 |
| Trading | ||
| Volume | 186,511 shares | KR#604/2,436 Sec#57/234 |
| Foreign Own. | 2.39% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -77 KRW | KR—/2,436 Sec—/234 |
| BPS | 7,596 KRW | KR#1,112/2,436 Sec#82/234 |
Company Info
Established in 1980 for pharmaceutical manufacturing and sales, the company founded its subsidiary, PharmBay, for specialized pharmaceutical distribution in 2020, which was listed on KOSDAQ in 2025. It specializes in cardiovascular treatments for hypertension and hyperlipidemia, as well as diabetes treatments, handling 126 professional pharmaceutical products. Cardiovascular drugs, diabetes drugs, and CMO business account for 47%, 10%, and 12% of sales, respectively, with the company enhancing competitiveness by expanding its chronic disease treatment lineup. Samik Pharm was founded in 1980 and is headquartered in Bupyeong-gu, Incheon.